MHC-presented DNP-modified tumor peptide (null)

MHC-presented DNP-modified tumor peptide refers to a peptide derived from tumor-associated proteins that has been chemically modified by the addition of a dinitrophenyl (DNP) group, then presented on the cell surface in complex with Major Histocompatibility Complex (MHC) class I or II molecules[3]. The DNP acts as a hapten, creating a “neoantigen” that can be recognized as non-self by the immune system, enabling cytotoxic T lymphocyte (CTL) recognition and anti-tumor activity even in cases where wild-type tumor peptides are ignored due to tolerance[1][3]. Structurally, DNP modifications are often placed on solvent-exposed residues within the peptide, allowing direct interaction with T-cell receptors[3]. Research in cell and animal models has shown the potential for DNP-modified MHC peptides to enhance antitumor immune responses compared to natural tumor peptides[1][3]. Therapeutic use is experimental, aimed at vaccine and immunotherapy strategies that break immunological tolerance to tumor antigens. Safety and clinical translation face challenges such as off-target reactivity and immunogenic variability[1][4].

Other names

DNP-modified MHC peptideDNP-peptide-MHC complexDinitrophenyl-modified MHC ligandChemically-modified tumor neoantigen (DNP)

The DNP modification creates a **neoantigen** when tumor peptides are presented on MHC molecules, enabling recognition by T-cell receptors that do not respond to the unmodified peptides[3]. This approach is intended to break tolerance and stimulate stronger immune responses against tumor cells by making the tumor peptides more immunogenic[1][3].